Maxcyte (MXCT) Raw Materials (2020 - 2026)

Maxcyte (MXCT) has 7 years of Raw Materials data on file, last reported at $3.5 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $3.5 million, down 21.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (down 21.82% YoY), and the FY2025 annual result was $3.9 million, down 18.08% from the prior year.
• Raw Materials slipped to $3.5 million in Q1 2026 per MXCT's latest filing, from $3.9 million in the prior quarter.
• Over five years, Raw Materials peaked at $6.0 million in Q1 2023 and troughed at $3.5 million in Q1 2026.
• A 5-year average of $4.9 million and a median of $5.2 million in 2022 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2022 and 2025: Raw Materials surged 224.18% in 2022, then plunged 30.53% in 2025.
• A 5-year view of Raw Materials shows it stood at $5.7 million in 2022, then gained by 0.76% to $5.7 million in 2023, then dropped by 17.16% to $4.7 million in 2024, then declined by 18.08% to $3.9 million in 2025, then slipped by 9.6% to $3.5 million in 2026.
• Business Quant data shows MXCT's Raw Materials at $3.5 million in Q1 2026, $3.9 million in Q4 2025, and $3.9 million in Q3 2025.